-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the research team of Han Zeguang from the Institute of Systems Biomedicine, Shanghai Jiao Tong University published an article titled DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma online in the well-known academic journal Liver International, revealing a novel targeting membrane protein DLK1.
Chimeric antigen receptor T cells (CAR-T) immunotherapy, as a promising method of adoptive T cell therapy, has achieved remarkable results in the treatment of hematological tumors , but also brought a new dawn for the treatment of solid tumors (Figure 1)
Figure 1.
In this study, DLK1 is a membrane protein and has important roles in liver development and tumorigenesis
Figure 2.
Figure 3.
This study provides a new CAR-T cell therapy targeting the membrane antigen DLK1, which has the potential to be further developed as a clinical immunotherapy for liver cancer
Prof.
Paper link: https://onlinelibrary.
Han Zeguang
Institute of Systems Biomedicine
